Clinical trials: Musculoskeletal Disease
Osteoarthritis
Intra-articular Polyacrylamide Hydrogel in Knee Osteoarthritis
The aim of this double-blinded controlled study is to assess clinical efficacy and safety of intra-articular HBISA Endoprosthesis of Synovial Fluid (polyacrylamide hydrogel) in comparison with placebo (0.9% sodium chloride…
- Trial name
- NCT03897686
- Testing
- hydrous biopolymer with silver ions "Argiform", saline solution
- Where
- 4 sites in Russia
- Volunteers
- 144 people
- Sponsor
- Research Centre BIOFORM
DM1, Myotonic Dystrophy 1
Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients
AOC 1001-CS1 is a randomized, double-blind, placebo-controlled, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple-doses of AOC 1001 Administered Intravenously to…
- Conditions
- DM1, Myotonic Dystrophy 1, Myotonic Dystrophy, Myotonic Dystrophy Type 1 (DM1)
- Trial name
- MARINA (NCT05027269)
- Testing
- AOC 1001
- Where
- 8 sites in United States
- Volunteers
- 39 people
- Sponsor
- Avidity Biosciences, Inc.
Rheumatoid Arthritis
An Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects With Rheumatoid Arthritis
A study comparing the use of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects with Rheumatoid Arthritis.
- Trial name
- NCT02565810
- Testing
- Adalimumab PFS and Pen
- Where
- 2 sites in Poland
- Volunteers
- 49 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Rheumatoid Arthritis
Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in Subjects With Rheumatoid Arthritis (RA)
The purpose of this study is to evaluate the safety of an additional 28 weeks of treatment with pegsunercept for subjects who have completed treatment in a previous double-blind study (20000201 or 20000198).
- Trial name
- NCT00111423
- Testing
- Pegsunercept (PEG sTNF-RI)
- Volunteers
- 216 people
- Sponsor
- Amgen
Degenerative Disc Disease
INDEPENDENCE Spacer for Lumbar Fusion
The primary objective of this study is to evaluate radiographic outcomes, intra-operative parameters, clinical outcomes, and patient satisfaction following circumferential fusion using the INDEPENDENCE® integrated plate and…
- Trial name
- NCT02299323
- Testing
- INDEPENDENCE
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Globus Medical Inc
Depression, Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women
Desvenlafaxine succinate (DVS) is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). The sustained-release (SR) formulation, DVS SR, is being studied in the development program for the treatment of…
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- NCT00369343
- Testing
- Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)
- Where
- 37 sites in United States
- Volunteers
- 381 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Arthritis, Psoriatic
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
This is a study to confirm the clinical efficacy and safety of sonelokimab compared with placebo in the treatment of adults with active psoriatic arthritis who have had a previous inadequate response or intolerance to anti-tumor…
- Trial name
- IZAR-2 (NCT06641089)
- Testing
- Sonelokimab, Risankizumab
- Where
- 143 sites in United States, Bulgaria and 9 more
- Volunteers
- 600 people
- Sponsor
- MoonLake Immunotherapeutics AG
Degenerative Lumbar Spondylolisthesis
OP-1 Putty for Posterolateral Fusions
The trial was designed to demonstrate the comparability of the overall success rate in the OP-1 Putty treatment group to the autograft treatment group.
- Trial name
- NCT00677950
- Testing
- Spinal fusion
- Where
- 24 sites in United States, Canada
- Volunteers
- 336 people
- Sponsor
- Olympus Biotech Corporation
Osteoarthritis, Knee
Calypso Knee System Clinical Study
A clinical study to evaluate the safety and effectiveness of the Calypso Knee System when used in subjects with symptomatic osteoarthritis of the medial compartment of the knee.
- Trial name
- NCT03671213
- Testing
- Calypso Knee System (Implantable Shock Absorber)
- Where
- 5 sites in United States
- Volunteers
- 81 people
- Sponsor
- Moximed
Lumbar Radiculopathy, Lumbar Disc Herniation
Randomized Evaluation of Lumbar Injection Effectiveness and Function
The goal of this clinical trial is to learn whether the Triojection® System is safe and effective for treating symptomatic lumbar radiculopathy (leg pain caused by nerve irritation or compression) resulting from a contained…
- Conditions
- Lumbar Radiculopathy, Lumbar Disc Herniation, Contained Herniated Lumbar Disc
- Trial name
- RELIEF (NCT07856810)
- Testing
- Triojection® System, Selective Nerve Root Block (SNRB)
- Volunteers
- 300 people
- Sponsor
- SpinaFX Medical Inc.
Osteoporosis
ROSPA - Record on Satisfaction of Patients With Actonel 35 mg Once a Week
To determine the satisfaction of subject with Actonel 35 mg Once a Week in the treatment of post-menopausal osteoporosis. Open, non-controlled, multi-center study.
- Trial name
- NCT00544180
- Testing
- Risedronate
- Where
- Israel
- Volunteers
- 7 people
- Sponsor
- Sanofi
Hyperuricemia, Gout
Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of LC350189
This will be a dose block-randomized, double-blind, active and placebo controlled, single and multiple dosing, dose-escalation study to evaluate tolerability, safety and pharmacokinetic / pharmacodynamic characteristics.
- Trial name
- NCT01361646
- Testing
- LC350189
- Where
- South Korea
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Growth Hormone Deficiency, Pediatric, hGH (Human Growth Hormone)
A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
A 52 week trial of TransCon hGH, a long-acting growth hormone product, versus human growth hormone therapy. TransCon hGH will be given once-a-week, human growth hormone (hGH) will be given daily.
- Conditions
- Growth Hormone Deficiency, Pediatric, hGH (Human Growth Hormone), Endocrine System Diseases, Hormones
- Trial name
- NCT02781727
- Testing
- Once weekly subcutaneous injection of TransCon hGH, Once daily subcutaneous injection of Genotropin
- Where
- 53 sites in United States, Armenia and 12 more
- Volunteers
- 162 people
- Sponsor
- Ascendis Pharma Endocrinology Division A/S
Healthy Volunteer, Muscular Dystrophies
Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers
This is a Phase 1 2-part, single-center, open-label study in healthy male volunteers. Part A will assess the absorption, metabolism, excretion, and pharmacokinetics of one oral dose of radiolabeled EDG-5506.
- Conditions
- Healthy Volunteer, Muscular Dystrophies, Muscular Disorders, Atrophic, Muscular Diseases
- Trial name
- NCT05730842
- Testing
- EDG-5506 Tablet, Radiolabeled EDG-5506 Suspension, Radiolabeled EDG-5506 Intravenous
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Edgewise Therapeutics, Inc.
Duchenne Muscular Dystrophy
Safety and Efficacy Study of PTC124 in Duchenne Muscular Dystrophy
In some patients with Duchenne muscular dystrophy (DMD), the disease is caused by a nonsense mutation (premature stop codon) in the gene that makes the dystrophin protein.
- Trial name
- NCT00264888
- Testing
- PTC124
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- PTC Therapeutics
Velo-cardio-facial Syndrome, Psychosis
Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial Syndrome
This is an exploratory clinical investigation. The objectives of this study are to evaluate the safety, steady-state pharmacokinetics, and efficacy of metyrosine (Demser®) for the treatment of psychosis in patients with…
- Trial name
- NCT01127503
- Testing
- Metyrosine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Bausch Health Americas, Inc.
Osteoarthritis
Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement
A4091064 is a multicenter, long-term observational study of subjects from tanezumab interventional studies (regardless of treatment group) who undergo a total knee, hip or shoulder replacement during participation in the study.
- Trial name
- NCT02674386
- Testing
- Investigational Medical Product (IMP) administered in parent study
- Where
- 79 sites in United States, Australia and 13 more
- Volunteers
- 154 people
- Sponsor
- Pfizer
Osteoarthritis of the Knee
A Phase III Study of CLS2901C in Patients With Osteoarthritis of the Knee
To evaluate the efficacy and safety of CLS2901C human allogenic chondrocyte sheets used in the osteotomy + RMSC group compared to in the osteotomy alone group of patients with osteoarthritis of the knee (OAK).
- Trial name
- NCT06549686
- Testing
- CLS2901C (human [allogeneic] chondrocyte sheets)
- Where
- 6 sites in Japan
- Volunteers
- 96 people
- Sponsor
- CellSeed Inc.
Degenerative Disc Disease, Grade 1 Spondylolisthesis
Retrospective Study With Patients Treated With STALIF® C or M and Ti or FLX Implants for 1 and 2 Levels
This is a Retrospective, Observational Multi-Center study, utilizing patients diagnosed with up to a Grade1 spondylolisthesis or retrolisthesis or symptomatic degenerative disc disease and treated with STALIF® C, or M, Ti and/or…
- Conditions
- Degenerative Disc Disease, Grade 1 Spondylolisthesis, Retrolisthesis, Symptomatic Cervical Disc Disease
- Trial name
- Stalif (NCT05610397)
- Testing
- STALIF®
- Volunteers
- 200 people
- Sponsor
- Centinel Spine
Post Polio Syndrome, PPS
Efficacy and Safety of Xepol (Human Immunoglobulin) in Subjects With Post-Polio Syndrome (PPS)
The primary objective was to assess the effect of Xepol compared to placebo on physical health and on muscle strength in subjects with post-polio syndrome.The secondary objective was to assess the effect of Xepol compared to…
- Trial name
- NCT00160082
- Testing
- Xepol
- Where
- 4 sites in Sweden
- Volunteers
- 124 people
- Sponsor
- Calliditas Therapeutics AB
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.